The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Nuvation Bio Inc (NYSE: NUVB) closed at $9.52 in the last session, up 1.93% from day before closing price of $9.34. In other words, the price has increased by $1.93 from its previous closing price. On the day, 2.34 million shares were traded. NUVB stock price reached its highest trading level at $9.56 during the session, while it also had its lowest trading level at $9.2.
Ratios:
We take a closer look at NUVB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.39 and its Current Ratio is at 8.48. In the meantime, Its Debt-to-Equity ratio is 0.64 whereas as Long-Term Debt/Eq ratio is at 0.60.
On November 19, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $12.
On September 30, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $10.Jefferies initiated its Buy rating on September 30, 2025, with a $10 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 01 ’25 when Liu Dongfang sold 150,000 shares for $7.82 per share. The transaction valued at 1,173,255 led to the insider holds 18,000 shares of the business.
DONGFANG LIU bought 150,000 shares of NUVB for $1,173,255 on Dec 01 ’25. On Nov 26 ’25, another insider, Liu Dongfang, who serves as the CHIEF MEDICAL OFFICER of the company, sold 10,000 shares for $8.00 each. As a result, the insider received 80,000 and left with 18,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NUVB now has a Market Capitalization of 3263774464 and an Enterprise Value of 2772277248. For the stock, the TTM Price-to-Sale (P/S) ratio is 122.37 while its Price-to-Book (P/B) ratio in mrq is 10.01. Its current Enterprise Value per Revenue stands at 103.644 whereas that against EBITDA is -11.973.
Stock Price History:
The Beta on a monthly basis for NUVB is 1.56, which has changed by 2.4492753 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, NUVB has reached a high of $9.75, while it has fallen to a 52-week low of $1.54. The 50-Day Moving Average of the stock is 47.33%, while the 200-Day Moving Average is calculated to be 175.42%.
Shares Statistics:
According to the various share statistics, NUVB traded on average about 8.68M shares per day over the past 3-months and 6139660 shares per day over the past 10 days. A total of 341.76M shares are outstanding, with a floating share count of 239.39M. Insiders hold about 30.38% of the company’s shares, while institutions hold 53.82% stake in the company. Shares short for NUVB as of 1765756800 were 45976518 with a Short Ratio of 5.30, compared to 1763078400 on 66349138. Therefore, it implies a Short% of Shares Outstanding of 45976518 and a Short% of Float of 21.85.
Earnings Estimates
Currently, 1.0 analysts are dedicated to thoroughly evaluating and rating the performance of Nuvation Bio Inc (NUVB) in the stock market.The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.12 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$0.45 and -$0.45 for the fiscal current year, implying an average EPS of -$0.45. EPS for the following year is -$0.28, with 1.0 analysts recommending between -$0.28 and -$0.28.
Revenue Estimates
According to 8 analysts,. The current quarter’s revenue is expected to be $32.58M. It ranges from a high estimate of $49.8M to a low estimate of $16.21M. As of. The current estimate, Nuvation Bio Inc’s year-ago sales were $5.71MFor the next quarter, 8 analysts are estimating revenue of $30.8M. There is a high estimate of $36.7M for the next quarter, whereas the lowest estimate is $22.3M.
A total of 9 analysts have provided revenue estimates for NUVB’s current fiscal year. The highest revenue estimate was $70.8M, while the lowest revenue estimate was $37.25M, resulting in an average revenue estimate of $54.54M. In the same quarter a year ago, actual revenue was $7.87MBased on 9 analysts’ estimates, the company’s revenue will be $173.75M in the next fiscal year. The high estimate is $207.7M and the low estimate is $126.2M.
